|
?:abstract
|
-
Background: More than 26,760,000 cases of SARS-CoV-2 infection have been reported globally to date This study aimed to analyze the impact of new electronic communication tools in the diagnosis and treatment of patients with SARS-CoV-2 infection Methods: From January 20 to February 26, 2020, adult patients with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who were treated in The Fifth Affiliated Hospital, Sun Yat-sen University, in Zhuhai, China, were recruited Forty-seven eligible patients were enrolled and randomly classified into either the test group or the control group All of the patients received the standard therapeutic regimen and routine ward rounds The test group was subdivided into three subgroups: the first subgroup (5-minute group) was given an extra 5-minute ward round by WeChat voice call once daily for basic disease communication;the second subgroup (10-minute group) received an extra 10-minute ward round by WeChat voice call once daily for further detail;and the third subgroup (20-minute group) was given an extra 10-minute ward round via WeChat voice call once daily, as well as an extra 10 minutes every 3 days The primary outcome was the duration of positive-to-negative conversion of SARS-CoV-2 nucleic acid diagnosed by the NAT (nucleic acid testing) Results: In the test groups, the median time from diagnosis to the endpoint was 7 0 days [interquartile range (IQR), 3 8-10 8], compared with 10 0 days (IQR, 6 5-14 5) in the control group It showed significant reduced the duration time of virus from positive to negative by the NAT (nucleic acid testing), (P=0 032) especially between the 10-minute subgroup (3 0 days;IQR, 3 0-7 5) and the control group (P=0 0065) Conclusions: The use of new modes of electronic communication can benefit patients during the COVID-19 pandemic and could be extremely valuable in addressing the shortage of medical protective equipment and reducing occupational risk of exposure to infection
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}